Bone densitometry and vertebral fracture assessment

Current Osteoporosis Reports

Volumn 8, Issue 3, 2010, Pages 123-130

  Lewiecki, E Michael ^a  

^a NEW MEXICO CLINICAL RESEARCH AND OSTEOPOROSIS CENTER   (United States)

Author keywords

BMD; DXA; FRAX; Monitoring; Nonresponder; Osteoporosis; Responder; VFA

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; IBANDRONIC ACID; PARATHYROID HORMONE[1-34]; PLACEBO; RALOXIFENE; SALCATONIN; STRONTIUM RANELATE;

BONE DENSITOMETRY; BONE DENSITY; BONE FRAGILITY; CLINICAL ASSESSMENT; CLINICAL ASSESSMENT TOOL; CLINICAL CLASSIFICATION; CLINICAL PRACTICE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE SEVERITY; DRUG EFFICACY; DUAL ENERGY X RAY ABSORPTIOMETRY; FRACTURE; FRACTURE HEALING; FRACTURE RISK ASSESSMENT TOOL; GOVERNMENT REGULATION; HEALTH CARE ACCESS; HUMAN; INSTRUMENT VALIDATION; INTERMETHOD COMPARISON; IONIZING RADIATION; MEDICARE; OSTEOPOROSIS; PATIENT MONITORING; PREDICTION; QUALITY ADJUSTED LIFE YEAR; QUALITY CONTROL; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK REDUCTION; SENSITIVITY AND SPECIFICITY; SPINE RADIOGRAPHY; TREATMENT PLANNING; VERTEBRA FRACTURE; ALGORITHM; COMPLICATION; LUMBAR VERTEBRA; PATHOPHYSIOLOGY; PHOTON ABSORPTIOMETRY; PHYSIOLOGY; SPINAL FRACTURES; VERTEBRA;

ABSORPTIOMETRY, PHOTON; ALGORITHMS; BONE DENSITY; HUMANS; LUMBAR VERTEBRAE; OSTEOPOROSIS; RISK ASSESSMENT; SPINAL FRACTURES; THORACIC VERTEBRAE;

EID: 77955983292     PISSN: 15441873     EISSN: 15442241     Source Type: Journal    
DOI: 10.1007/s11914-010-0018-z     Document Type: Review

References (50)

1. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy 2001 Osteoporosis prevention, diagnosis, and therapy JAMA 285 785 795 10.1001/jama.285.6.785
2. • Kanis JA, on behalf of the World Health Organization Scientific Group: Assessment of Osteoporosis at the Primary Health-Care Level. Technical Report. Geneva, Switzerland: World Health Organization; 2007. This is a well-referenced detailed review of the rationale and methods for developing FRAX, the WHO computer-based fracture risk algorithm.
3. • World Health Organization: FRAX WHO Fracture Risk Assessment Tool. Available at http://www.shef.ac.uk/FRAX/. Accessed November 2009. The link to the online version of FRAX provides for input of BMD and VFA for estimation of the 10-year probability of fracture. This website is periodically updated to account for new data and the addition of new countries.
4. S Baim N Binkley JP Bilezikian, et al. 2008 Official Positions of the International Society for Clinical Densitometry and executive summary of the 2007 ISCD Position Development Conference J Clin Densitom 11 75 91 10.1016/j.jocd.2007.12.007 18442754 The ISCD Official Positions provide essential quality standards for the acquisition, analysis, interpretation, and reporting of BMD measurements and spine imaging with VFA
5. EM Lewiecki AJ Laster 2006 Clinical applications of vertebral fracture assessment by dual-energy x-ray absorptiometry J Clin Endocrinol Metab 91 4215 4222 10.1210/jc.2006-1178 1:CAS:528:DC%2BD28Xht1Whur%2FL 16940447
6. CV Albanese E Diessel HK Genant 2003 Clinical applications of body composition measurements using DXA J Clin Densitom 6 75 85 10.1385/JCD:6:2:75 12794229
7. L Yang N Peel JA Clowes, et al. 2009 Use of DXA-based structural engineering models of the proximal femur to discriminate hip fracture J Bone Miner Res 24 33 42 10.1359/jbmr.080906 18767924
8. JC Lotz EJ Cheal WC Hayes 1991 Fracture prediction for the proximal femur using finite element models: Part I-Linear analysis J Biomech Eng 113 353 360 10.1115/1.2895412 1:STN:280:DyaK387gs1yjsw%3D%3D 1762430
9. D Marshall O Johnell H Wedel 1996 Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures BMJ 312 1254 1259 1:STN:280:DyaK283isFejtw%3D%3D 8634613
10. WHO Study Group on Assessment of Fracture Risk and its Application to Screening for Postmenopausal Osteoporosis: Assessment of Fracture Risk and Its Application to Screening for Postmenopausal Osteoporosis. Geneva Technical Report Series 843. Geneva, Switzerland: World Health Organization; 1994.
11. A Cranney P Tugwell G Wells G Guyatt 2002 Systematic reviews of randomized trials in osteoporosis: introduction and methodology Endocr Rev 23 497 507 1:CAS:528:DC%2BD38Xnt1Witbo%3D
12. RD Wasnich PD Miller 2000 Antifracture efficacy of antiresorptive agents are related to changes in bone density J Clin Endocrinol Metab 85 231 236 10.1210/jc.85.1.231 1:STN:280:DC%2BD3c%2Fpslymug%3D%3D 10634392
13. R Mazess CH Chesnut III M McClung H Genant 1992 Enhanced precision with dual-energy X-ray absorptiometry Calcif Tissue Int 51 14 17 10.1007/BF00296209 1:STN:280:DyaK3s%2FgslCisA%3D%3D 1393769
14. CF Njeh T Fuerst D Hans, et al. 1999 Radiation exposure in bone mineral density assessment Appl Radiat Isot 50 215 236 10.1016/S0969-8043(98)00026-8 1:CAS:528:DyaK1MXnsVSntA%3D%3D 10028639
15. RP Crawford CE Cann TM Keaveny 2003 Finite element models predict in vitro vertebral body compressive strength better than quantitative computed tomography Bone 33 744 750 10.1016/S8756-3282(03)00210-2 14555280
16. G Guglielmi TF Lang 2002 Quantitative computed tomography Semin Musculoskelet Radiol 6 219 227 10.1055/s-2002-36719 12541199
17. EM Lewiecki B Richmond PD Miller 2006 Uses and misuses of quantitative ultrasonography in managing osteoporosis Cleve Clin J Med 73 742 752 10.3949/ccjm.73.8.742 16913198
18. A Cranney SA Jamal JF Tsang, et al. 2007 Low bone mineral density and fracture burden in postmenopausal women CMAJ 177 575 580 17846439
19. SR Cummings DB Karpf F Harris, et al. 2002 Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs Am J Med 112 281 289 10.1016/S0002-9343(01)01124-X 1:CAS:528:DC%2BD38XhvVWkurk%3D 11893367
20. MC Hochberg S Greenspan RD Wasnich, et al. 2002 Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents J Clin Endocrinol Metab 87 1586 1592 10.1210/jc.87.4.1586 1:CAS:528:DC%2BD38XivFKlt7k%3D 11932287
21. EM Lewiecki NB Watts 2008 Assessing response to osteoporosis therapy Osteoporos Int 19 1363 1368 10.1007/s00198-008-0661-8 1:CAS:528: DC%2BD1cXhtVOiu7fI 18546030
22. DM Black SR Cummings DB Karpf, et al. 1996 Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures Lancet 348 1535 1541 10.1016/S0140-6736(96)07088-2 1:CAS:528: DyaK2sXisFCktQ%3D%3D 8950879
23. SR Cummings DM Black DE Thompson, et al. 1998 Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial JAMA 280 2077 2082 10.1001/jama.280.24.2077 1:CAS:528:DyaK1MXjsVWruw%3D%3D 9875874
24. B Ettinger DM Black BH Mitlak, et al. 1999 Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators JAMA 282 637 645 10.1001/jama.282.7. 637 1:CAS:528:DyaK1MXlvVKqurg%3D 10517716
25. SR Cummings L Palermo W Browner, et al. 2000 Monitoring osteoporosis therapy with bone densitometry: misleading changes and regression to the mean. Fracture Intervention Trial Research Group JAMA 283 1318 1321 10.1001/jama.283.10.1318 1:STN:280:DC%2BD3c7nslaisQ%3D%3D 10714731
26. L Lenchik NB Watts 2001 Regression to the mean: what does it mean? Using bone density results to monitor treatment of osteoporosis J Clin Densitom 4 1 4 10.1385/JCD:4:1:01 1:STN:280:DC%2BD3M3itVSitA%3D%3D 11309514
27. SL Bonnick 2000 Monitoring osteoporosis therapy with bone densitometry: a vital tool or regression toward mediocrity? J Clin Endocrinol Metab 85 3493 3495 10.1210/jc.85.10.3493 1:CAS:528:DC%2BD3cXnsFOgsLY%3D 11061488
28. KJ Bell A Hayen P Macaskill, et al. 2009 Value of routine monitoring of bone mineral density after starting bisphosphonate treatment: secondary analysis of trial data BMJ 338 b2266 10.1136/bmj.b2266 19549996
29. NB Watts EM Lewiecki SL Bonnick, et al. 2009 Clinical value of monitoring BMD in patients treated with bisphosphonates for osteoporosis J Bone Miner Res 24 1643 1646 10.1359/jbmr.090818 1:CAS:528:DC%2BD1MXhtlGgurbK 19712042
30. EM Lewiecki LA Rudolph 2002 How common is loss of bone mineral density in elderly clinical practice patients receiving oral bisphosphonate therapy for osteoporosis? J Bone Miner Res 17 Suppl 2 S367
31. EM Lewiecki 2003 Nonresponders to osteoporosis therapy J Clin Densitom 6 307 314 10.1385/JCD:6:4:307 14716042
32. ML Bouxsein PD Delmas 2008 Considerations for development of surrogate endpoints for antifracture efficacy of new treatments in osteoporosis: a perspective J Bone Miner Res 23 1155 1167 10.1359/jbmr.080301 18318643
33. NB Watts PD Miller LA Kohlmeier, et al. 2009 Vertebral fracture risk is reduced in women who lose femoral neck bone mineral density with teriparatide treatment J Bone Miner Res 24 1125 1131 10.1359/jbmr.081256 1:CAS:528: DC%2BD1MXmvFyjt70%3D 19113918
34. GM Blake EM Lewiecki DL Kendler I Fogelman 2007 A review of strontium ranelate and its effect on DXA scans J Clin Densitom 10 113 119 10.1016/j.jocd.2007.01.002 17485027
35. C Cooper T O'Neill A Silman 1993 The epidemiology of vertebral fractures. European Vertebral Osteoporosis Study Group Bone 14 Suppl 1 S89 S97 10.1016/8756-3282(93)90358-H 8110529
36. HK Genant CY Wu C Van Kuijk MC Nevitt 1993 Vertebral fracture assessment using a semiquantitative technique J Bone Miner Res 8 1137 1148 10.1002/jbmr.5650080915 1:STN:280:DyaK2c%2FlsFyhuw%3D%3D 8237484
37. JT Schousboe CR DeBold 2006 Reliability and accuracy of vertebral fracture assessment with densitometry compared to radiography in clinical practice Osteoporos Int 17 281 289 10.1007/s00198-005-2010-5 16172798
38. DM Black NK Arden L Palermo, et al. 1999 Prevalent vertebral deformities predict hip fractures and new vertebral fractures but not wrist fractures J Bone Miner Res 14 821 828 10.1359/jbmr.1999.14.5.821 1:STN:280:DyaK1M3lsFyjtw%3D%3D 10320531
39. L Ferrar G Jiang R Eastell NF Peel 2003 Visual identification of vertebral fractures in osteoporosis using morphometric X-ray absorptiometry J Bone Miner Res 18 933 938 10.1359/jbmr.2003.18.5.933 1:STN:280: DC%2BD3s3ht1Cmtg%3D%3D 12733735
40. M Van der Klift CE De Laet EV McCloskey, et al. 2002 The incidence of vertebral fractures in men and women: the Rotterdam Study J Bone Miner Res 17 1051 1056 10.1359/jbmr.2002.17.6.1051 12054160
41. National Osteoporosis Foundation: Clinician's Guide to Prevention and Treatment of Osteoporosis. Washington, DC: National Osteoporosis Foundation; 2008.
42. JT Schousboe KE Ensrud JA Nyman, et al. 2005 Potential cost-effective use of spine radiographs to detect vertebral deformity and select osteopenic post-menopausal women for amino-bisphosphonate therapy Osteoporos Int 16 1883 1893 10.1007/s00198-005-1956-7 16133649
43. ED Newman TP Oleginski JL Perruquet JL Hummer 2005 Vertebral fracture analysis using DXA- a clinically important and inexpensive method to improve osteoporosis risk assessment [abstract] Arthritis Rheum 52 Suppl S677
44. JA Kanis IP Barton O Johnell 2005 Risedronate decreases fracture risk in patients selected solely on the basis of prior vertebral fracture Osteoporos Int 16 475 482 10.1007/s00198-004-1698-y 1:CAS:528:DC%2BD2MXlsFSku7Y%3D 15875093
45. SA Quandt DE Thompson DL Schneider, et al. 2005 Effect of alendronate on vertebral fracture risk in women with bone mineral density T scores of -1.6 to -2.5 at the femoral neck: the Fracture Intervention Trial Mayo Clin Proc 80 343 349 10.4065/80.3.343 1:CAS:528:DC%2BD2MXis1SltL0%3D 15757015
46. CH Chesnut III A Skag C Christiansen, et al. 2004 Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis J Bone Miner Res 19 1241 1249 10.1359/JBMR.040325 1:CAS:528:DC%2BD2cXntFGqurw%3D
47. RM Neer CD Arnaud JR Zanchetta, et al. 2001 Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis N Engl J Med 344 1434 1441 10.1056/NEJM200105103441904 1:CAS:528:DC%2BD3MXktVSgsbw%3D 11346808
48. EM Lewiecki N Binkley SM Petak 2006 DXA quality matters J Clin Densitom 9 388 392 10.1016/j.jocd.2006.07.002 17097522
49. JA Kanis O Johnell 2005 Requirements for DXA for the management of osteoporosis in Europe Osteoporos Int 16 229 238 10.1007/s00198-004-1811-2 1:STN:280:DC%2BD2M%2Fps1Shtg%3D%3D 15618996
50. EM Lewiecki S Baim ES Siris 2008 Osteoporosis care at risk in the United States Osteoporos Int 19 1505 1509 10.1007/s00198-008-0716-x 1:STN:280:DC%2BD1cnksV2jtg%3D%3D 18758881